Ralliant (NYSE:RAL) Coverage Initiated by Analysts at Evercore

Evercore initiated coverage on shares of Ralliant (NYSE:RAL) in a report released on Tuesday. The firm set an “outperform” rating and a $80.00 price target on the stock. Evercore’s target price would indicate a potential upside of 25.38% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Citigroup lifted their price objective on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Oppenheimer increased their target price on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Barclays raised their price target on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Finally, TD Cowen lifted their price target on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $67.30.

Ralliant Stock Up 4.6%

RAL stock traded up $2.78 during mid-day trading on Tuesday, reaching $63.81. The company had a trading volume of 59,398 shares, compared to its average volume of 1,681,750. The firm has a fifty day simple moving average of $51.16 and a 200 day simple moving average of $49.32. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The company has a market capitalization of $7.14 billion and a price-to-earnings ratio of -5.82. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $64.04.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.Ralliant’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Analysts forecast that Ralliant will post 2.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Allworth Financial LP lifted its position in Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares during the last quarter. Rothschild Investment LLC increased its position in shares of Ralliant by 98.1% during the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock worth $31,000 after purchasing an additional 303 shares in the last quarter. Keybank National Association OH increased its position in shares of Ralliant by 1.6% during the fourth quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock worth $1,001,000 after purchasing an additional 305 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Ralliant by 49.6% in the 4th quarter. UMB Bank n.a. now owns 983 shares of the company’s stock valued at $50,000 after purchasing an additional 326 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its position in shares of Ralliant by 1.5% in the 4th quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock valued at $1,117,000 after purchasing an additional 329 shares during the period.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.